Product logins

Find logins to all Clarivate products below.


The drug profile includes the sales and forecast for the time period 2017 – 2028 for the United States and Rest of the World (ROW). It also covers the forecast summary and assumptions in terms of upsides and downsides.

Related Market Assessment Reports

Report
Influenza Vaccine – Epidemiology – Epidemiology | Influenza Vaccine – Mature Markets
Clarivate Epidemiology’s coverage of the influenza vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Report
Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast
Pre-exposure prophylaxis (PrEP) is a key prevention strategy for ending the human immunodeficiency virus (HIV) epidemic. The FDA’s approval of Gilead’s Truvada in 2012 and Descovy in 2019…
Report
Non-Small-Cell Lung Cancer | China In-Depth | China | 2022
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies…
Report
Rheumatoid Arthritis | Disease Landscape & Forecast | G7 | 2022
Although the tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first…
Report
Asthma | Disease Landscape & Forecast | G7 | 2022
The asthma therapy market consists of many well-established treatments, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s…